1/20
High-yield vocabulary and core concepts for NEET PG review on hypertensive disorders of pregnancy, including diagnostic thresholds, pharmacology, complications, and management protocols.
Chronic hypertension in pregnancy
Hypertension present prior to pregnancy, diagnosed before 20 weeks of gestation, or persisting beyond 12 weeks postpartum.
Gestational hypertension
New blood pressure elevation with systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg arising after 20 weeks of gestation without proteinuria or maternal end-organ dysfunction.
Preeclampsia
New-onset hypertension presenting after 20 weeks of gestation accompanied by proteinuria or evidence of maternal end-organ dysfunction; proteinuria is not mandatory for diagnosis when end-organ features exist.
Preeclampsia superimposed on chronic hypertension
Pre-existing chronic hypertension accompanied by new-onset proteinuria, a sudden worsening of blood pressure or proteinuria, or the emergence of new maternal end-organ dysfunction.
Eclampsia
New-onset generalized seizures occurring in a patient with preeclampsia that are not attributable to other neurological causes.
Severe-range blood pressure in pregnancy
Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg, requiring urgent hospital confirmation and prompt medical intervention.
Diagnostic proteinuria criteria in preeclampsia
Urinary protein excretion of ≥300 mg in a 24-hour urine collection, a urine protein/creatinine ratio ≥0.3, or a dipstick measurement of 2+ when quantitative tests are unavailable.
Non-proteinuric preeclampsia end-organ criteria
Diagnostic criteria enabling preeclampsia diagnosis without proteinuria in a hypertensive woman: platelets <100,000/μL, serum creatinine >1.1 mg/dL (or doubling of baseline), transaminases ≥2× upper limit of normal or severe persistent epigastric/RUQ pain, pulmonary edema, or new cerebral/visual symptoms.
Pathophysiology of preeclampsia
Defective trophoblast invasion causing incomplete remodeling of spiral arteries into low-resistance vessels, leading to high-resistance uteroplacental circulation, placental ischemia, release of anti-angiogenic factors (elevated sFlt-1 and soluble endoglin; reduced free VEGF and PlGF), and widespread maternal endothelial injury.
Low-dose aspirin prophylaxis
Preventive regimen of 75–150 mg orally once daily initiated at 12 weeks (ideally prior to 16 weeks) in pregnant individuals identified as high-risk or with qualifying moderate-risk factors.
First-line maintenance antihypertensives in pregnancy
Oral medications used for the routine management of chronic or non-severe gestational hypertension, specifically oral labetalol, nifedipine, or methyldopa.
Contraindicated antihypertensives in pregnancy
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), which are contraindicated during pregnancy due to fetotoxicity; atenolol is avoided due to an association with fetal growth restriction.
Acute severe hypertension therapy in pregnancy
Urgent hospital therapies indicated for severe-range blood pressure (≥160/110 mmHg), consisting of IV labetalol, IV hydralazine, or oral immediate-release nifedipine (sublingual nifedipine is avoided).
Magnesium sulfate (MgSO4)
The drug of choice for the prevention and treatment of eclamptic seizures; acts as an anticonvulsant, not an antihypertensive agent.
Pritchard regimen
An eclampsia protocol consisting of an initial loading dose of 4 g IV slowly plus 10 g IM (5 g in each buttock), followed by maintenance doses of 5 g IM every 4 hours alternating buttocks.
Zuspan regimen
An intravenous magnesium sulfate regimen consisting of a 4 g IV loading dose followed by a continuous infusion of 1–2 g/hour.
Magnesium sulfate safety monitoring parameters
Clinical assessments required prior to each maintenance dose: presence of the patellar reflex (knee jerk), maternal respiratory rate ≥12/min, and urinary output ≥25–30 mL/hour.
Calcium gluconate antidote
The specific antidote for magnesium sulfate toxicity, administered as 1 g IV (10 mL of a 10% solution) slowly to reverse loss of deep tendon reflexes, respiratory depression, or cardiac arrest.
Delivery timing in preeclampsia
Definitive management recommended at 37 weeks for gestational hypertension or preeclampsia without severe features, and at ≥34 weeks following maternal stabilization in preeclampsia with severe features (or any gestational age upon clinical deterioration).
HELLP syndrome
A severe preeclampsia variant characterized by the triad of Hemolysis, Elevated Liver enzymes, and Low Platelets.
Tennessee criteria
Diagnostic laboratory thresholds for complete HELLP syndrome: total LDH ≥600 IU/L, AST ≥70 IU/L, and platelet count <100,000/μL.